Resumen
Los trastornos del control de impulsos (TCI) son complicaciones psiquiátricas de la enfermedad de Parkinson (EP), cada vez más reconocidos, pero que persisten subdiagnosticados y pueden llegar a ser muy disruptivos para la vida familiar del paciente, en especial si no son detectados a tiempo. Si bien uno de sus principales riesgos es el uso de agonistas dopaminérgicos, estos no son su única causa, se pueden ver sin relación con medicamentos o con cualquier tratamiento para la EP. Por lo tanto, se debe interrogar sistemáticamente por su presencia y educar al paciente y su familia para que sean reportados en cualquier momento. El objetivo de este capítulo es describir los diferentes tipos de TCI, sus factores de riesgo y tratamiento.
Citas
Vargas A, Cardoso F. Impulse control and related disorders in Parkinson's disease. Arq Neuropsiquiatr. 2018;76(6):399-410.
Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson's disease. Int Rev Neurobiol. 2017;133:679-717.
Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disor. 2009;24:1561-70.
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-95.
Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017;88:317-24.
Vela L, Martínez Castrillo JC, García Ruiz P, Gasca-Salas C, Macías Y, Pérez Fernández E, et al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. J Neurol Sci. 2016;368:150-4.
Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, et al. Impulsivity and compulsivity in drugnaiive patients with Parkinson's disease. Mov Disord. 2011;26:464-8.
Sáez-Francàs N, Martí Andrés G, Ramírez N, Fàbreugues O, Alvarez-Sabin J, Casas M, et al. Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. Neurología. 2016;31:231-8.
Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-4.
Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, et al. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord. 2011;17:635-7.
de Chazeron I, Llorca PM, Chéreau-Boudet I, Blanc O, Perriot J, Ouchchane L et al. Hypersexuality and pathological gambling in Parkinson's disease: A cross-sectional case-control study. Mov Disord. 2011;26:2127-30.
Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord. 2012;18:155-60.
Ramírez Gómez CC, Serrano Dueñas M, Bernal O, Araoz N, Sáenz Farret M, Aldinio V, et al. A Multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. 2017;40:51-55.
Isaias-Millan S, Pina-Fuentes D, Guzman-Astorga C, Cervantes-Arriaga A, Rodríguez-Violante M. Prevalencia de trastornos neuropsiquiátricos en pacientes con enfermedad de Parkinson (EP) no tratados. Gac Med Mex. 2016;152:357-63.
Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Camacho-Ordoñez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsionism Relat Disord. 2014;20:907-10.
Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in Parkinson disease: a multicenter case: control study. Ann Neurol. 2011;69:986-96.
Bernal-Pacheco O, Murcia DC. Impulsividad secundaria a agonistas dopa, una cifra más allá de la esperada. Poster VII Simposio Internacional de Movimientos Anormales. Cartagena, agosto 24-26 2017.
Siri C, Cilia R, Reali E, Pozzi B, Cereda E, Colombo A, et al. Longterm cognitive follow-up of Parkinson's disease patients with impulse control disorders. Mov Disord. 2015;30:696-704.
Morgante F, Fasano A, Ginevrino M, Petrucci S, Ricciardi L, Bove F, et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology. 2016;87:1436-41.
Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68:963-8.
Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68:400-4.
Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80:792-9.
Merola A, Romagnolo A, Rizzi L, Rizzone MG, Zibetti M, Lanotte M, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol. 2017;264:40-8.
Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2012;18:1079-83.
Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekçi S, Erginõz E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16:334-7.
Spencer AH, Rickards H, Fasano A, Cavanna AE. The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord. 2011;26:578-86.
Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85:311-8
Catalán MJ, Pablo-Fernández E, Villanueva C, Fernández-Diez S, Lapeña-Montero T, García-Ramos R, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord. 2013;28:2007-10.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.